Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background & Aims: Patients with advanced cirrhosis often have immune dysfunction and are more susceptible to infections. Galectin-3 is a β-galactoside-binding lectin implicated in inflammation, immune regulation and liver fibrosis. We aim to investigate galectin-3 expression in advanced cirrhosis and its ability to predict post-transplant infectious complications.
Methods: We collected sera and liver samples from 129 cirrhotic patients at the time of liver transplantation and from an external cohort of 37 patients with alcoholic liver disease including alcoholic hepatitis (AH) at the time of diagnosis. Galectin-3 was assessed by ELISA, real-time PCR, immunohistochemistry and RNA-seq. Receiver operating characteristic curves and Cox proportional-hazards regression analysis were performed to assess the predictive power of galectin-3 for disease severity and post-transplant infections.
Results: Increased galectin-3 levels were found in advanced cirrhosis. Galectin-3 significantly correlated with disease severity parameters and inflammatory markers. Galectin-3 had significant discriminating power for compensated and advanced cirrhosis (AUC = 0.78/0.84, circulating/liver galectin-3; p < .01), and was even higher to discriminate severe AH (AUC = 0.95, p < .0001). Cox Proportional-hazard model showed that galectin-3, MELD-Na and the presence of SIRS predict the development of post-transplant infectious complications. Patients with circulating galectin-3 (>16.58 ng/ml) were at 2.19-fold 95% CI (1.12-4.29) increased risk, but when combined with MELD-Na > 20.0 and SIRS, the risk to develop post-transplant infectious complications, increased to 4.60, 95% CI (2.38-8.90).
Conclusion: Galectin-3 is a novel biological marker of active inflammation and disease severity that could be clinically useful alone or in combination with other scores to discriminate advanced cirrhosis and predict post-transplant infectious complications.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/liv.15326 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Poricoic Acid A attenuated TGF-β1-induced epithelial-mesenchymal transition in renal tubular epithelial cells through SPRY2/ERK signaling pathway.
Korean J Physiol Pharmacol
September 2025
Department of Endocrinology, The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan 410007, China.
The progression of renal fibrosis is difficult to reverse, and Poria cocos, one of the main components of Wenyang Zhenshuai Granules, has been shown to be crucial to the development of the epithelial-mesenchymal transition (EMT). This study aimed to examine the molecular mechanism by which Poricoic Acid A (PAA) inhibited the advancement of EMT in renal tubular epithelial (RTE) cells. The protein levels of sprouty RTK signaling antagonist 2 (SPRY2) extracellular regulated protein kinases (ERK), and p-ERK were measured.
View Article and Find Full Text PDFCone Unit-Based Anatomical Liver Resection Guided by Preoperative Embolization and ICG Fluorescence: A Novel Surgical Strategy.
Ann Surg Oncol
September 2025
Carle Illinois College of Medicine University of Illinois Urbana-Champaign, 509 W University Ave, Urbana, IL, 61801, USA.
Background: The liver cone unit (Tokyo 2020 terminology) of the peripheral portal vein territory represents the smallest anatomical and functional unit of the liver. While this unit enables anatomical, subsegmental resection, particularly in patients with cirrhosis, the tumor-bearing cone unit can be challenging to identify intraoperatively. PATIENTS AND METHODS: A 58-year-old man with hepatitis C-related cirrhosis (Child-Pugh B) was diagnosed with a subcapsular hepatocellular carcinoma (HCC) in segment 8.
View Article and Find Full Text PDFDeveloping a collaborative network for cystic fibrosis in Africa: A call to action.
J Cyst Fibros
September 2025
Division of Paediatric Pulmonology; University of Cape Town, South Africa; Red Cross War Memorial Children's Hospital, Cape Town, South Africa.
Background: Cystic fibrosis (CF) is a genetic disorder that remains underrecognized across Africa, where limited diagnostic capacity, low awareness, and competing health priorities contribute to delayed or missed diagnoses [1-4]. Although increasing data suggests CF is more prevalent than previously believed in Africa, survival remains poor [1]. These challenges do not only affect people with CF (pwCF) in Africa but also have implications for global understanding of the disease, particularly among populations historically excluded from CF research and treatment advances.
View Article and Find Full Text PDFEvodiamine attenuates silica-induced pulmonary fibrosis via PI3K/AKT pathway suppression: Integrated computational and experimental validation.
Biochem Biophys Res Commun
September 2025
Guangdong Province Hospital for Occupational Diseases Prevention and Treatment, Guangzhou, China; School of Public Health, Southern Medical University, Guangzhou, China. Electronic address:
Background: Silicosis, a devastating occupational lung disease caused by silica dust inhalation, lacks effective treatment options. Evodiamine (Evo), a bioactive alkaloid, has demonstrated anti-fibrotic potential in various diseases; however, its efficacy in silicosis and underlying mechanisms remain elusive. This study aims to systematically investigate Evo's therapeutic effects and mechanisms against silicosis.
View Article and Find Full Text PDFNew insights into gut-liver axis in advanced liver diseases: A promising therapeutic target.
Biochem Pharmacol
September 2025
Department of Hepatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China. Electronic address:
The gut-liver axis constitutes a bidirectional communication network that integrates the ecological microenvironment, metabolism, and immune signals between the gut and liver systems. Currently, there is compelling evidence indicating that the overall dysfunction of the gut-liver axis is a pivotal driver in the pathogenesis of advanced liver diseases. This review focuses on the latest research progress regarding various components of the intestinal barrier and how these components contribute to the onset and progression of cirrhosis and its complications.
View Article and Find Full Text PDF